Kempen & Co's Gafanhao on the Curevac Covid-19 Vaccine

The video discusses CureVac's upcoming results, comparing them with Moderna's and Pfizer's mRNA vaccines. It highlights the impact of new variants on vaccine efficacy and Europe's strategy to adopt mRNA vaccines. The potential for mixed vaccine doses and the timeline for achieving herd immunity in Europe are also explored.

What is the expected protection rate for CureVac's vaccine compared to Moderna's?

• 80% to 95%

• 90% to 100%

• 50% to 70%

• 60% to 75%

How is the European Union responding to the challenges with AstraZeneca's vaccine?

• By banning all vaccines

• By increasing purchases of mRNA vaccines

• By developing a new vaccine

• By stopping all vaccinations

What is a potential strategy being considered for those who received the AstraZeneca vaccine?

• Receiving no second dose

• Receiving a different non-mRNA vaccine

• Receiving a second dose of an mRNA vaccine

• Receiving a second dose of AstraZeneca

What is the European Union's target for vaccination coverage by summer?

• 50% of the population

• 60% of the population

• 70% of the population

• 80% of the population

What is the current vaccination rate in Europe according to the World Health Organization?

• 5% to 10%

• 20% to 25%

• 15% to 20%

• 10% to 15%